The "Amazon Bio Discovery" research platform, launched today, does not display ads in its results or search a database, but it does have AI agentic technology and connect to some of its partners that support this project. 

Launched by Amazon Web Services (AWS) today, it's an AI-powered application for scientists and researchers in pharmaceutical companies, biotech startups, and academic institutions. It provides them with specialized AI models for drug discovery and an AI agent that can help generate and design potential drug molecules, which also is known as “drug candidates."

Once the most promising drug molecules are identified, they can send them to Amazon's lab partners for testing. Amazon has partnered with Memorial Sloan Kettering to support accelerated antibody design for potential pediatric cancer therapies that would take discovery from months to weeks. The goal is to "beat the clock" for terminal cancers and other diseases. 

Targeting a rare pediatric cancer, nearly 300,000 antibody molecules were designed using AI agents and multiple biological AI models, with the top 100,000 candidates sent for wet lab testing.

With the platform, a process that typically takes up to a year using traditional design methods took weeks -- from designing the candidates to sending them to lab testing, according to Memorial Sloan Kettering.

Amazon will not use ads to monetize the platform, but Amazon Bio Discovery does offer a subscription-based model, beginning with a free trial of five experiments before moving to paid-subscription tiers.

The launch marks Amazon’s entrance into the crowded field of drug discovery, and has sparked conversation around what an established player joining the space will mean for smaller startups currently raising capital, according to one media firm that represents several companies in the space.

Health services have emerged from many of the companies offering AI-based search services. Several major competitors have launched health-related chat apps. Amazon launched an agentic Health AI assistant in January 2026 within the One Medical app.

Similar to OpenAI Health ChatGPT launched in January, it provides personalized guidance based on medical records, explains lab results, and can book appointments or manage medications.

Anthropic has Claude for Healthcare, and Microsoft Copilot Health provides mental health support. Perplexity has an AI search engine that connects users to their medical records, wearables, and lab results.

The platform has a catalog of specialized AI models called biological foundation models (bioFMs) that are trained on biological datasets. These models generate and evaluate potential drug molecules, known as candidates, helping scientists accelerate antibody therapies during the early stages of drug discovery. But access alone is not enough.

During the past several years, progress in generative AI has created an explosion of new machine-learning models, ranging from predicting the physical structure of proteins to evaluating candidates based on their chemical properties.

These models have shown promise, but require coding skills and the ability to manage computing infrastructure.

Selecting models alone is challenging because there are dozens of such models, and it is difficult to benchmark them against each other.

As a result, many scientists struggle to use AI models independently, and computational biologists -- the experts who have specialized AI skills that could help them -- are in short supply.

Amazon’s platform addresses these challenges with three capabilities: a benchmarked library of AI models and analysis packages, an AI agent that helps researchers design experiments, and integrated lab partners that test the most promising antibody candidates and route results back to the scientists.

The loop that provides feedback improves the next round of designs, just as large language models do for advertising platforms.